CA 27-29 in patients with breast cancer with pulmonary fibrosis
4.8 (547) · $ 27.50 · In stock
A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).
Table 4 from Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis
Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing
PDF) sag-36-4-2-0601-1(1) Abdurrahman Coskun
Dr. Sobha Kurian, MD – Morgantown, WV
PDF] Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Current Oncology, Free Full-Text
Genes & Cancer A tumor specific antibody to aid breast cancer screening in women with dense breast tissue
Lung Cancer with Skin and Breast Metastasis: A Case Report and Literature Review
Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis. - Abstract - Europe PMC
Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report, BMC Cardiovascular Disorders
Dr. Mudussara A. Khan, MD, Daytona Beach, FL, Oncologist
:max_bytes(150000):strip_icc()/cancer-antigen-2729-430607-Final-b8a7e5951fbc46c6ac049816b15f9d0e.jpg)
Cancer Antigen 27.29 Test: Uses, Procedure, Results
